1
|
Salin AV, Shabanov AA, Khayarov KR, Nugmanov RI, Islamov DR. Stereoelectronic Effect in the Reaction of α-Methylene Lactones with Tertiary Phosphines and Its Application in Organocatalysis. J Org Chem 2023; 88:11954-11967. [PMID: 37540578 DOI: 10.1021/acs.joc.3c01223] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/06/2023]
Abstract
The kinetic data indicate that the addition of tertiary phosphines to α-methylene lactones in acetic acid is strongly accelerated in comparison to the reactions of related open-chain esters. Six-membered α-methylene-δ-valerolactone exhibited a more pronounced rate increase than five-membered α-methylene-γ-butyrolactone. The use of α-methylene-γ-butyrolactam as a nitrogen analogue of α-methylene-γ-butyrolactone resulted in a total loss of the reaction acceleration. The observed reactivities were rationalized by DFT calculations at the RwB97XD/6-31+G(d,p) level of theory, showing that the intramolecular interaction between phosphonium and enolate oxygen centers provided by the locked s-cis-geometry of the heterocycles plays an important role in the stabilization of intermediate zwitterions. The reactivity is also controlled by the conformational flexibility of the heterocycle. The geometries of five-membered and, especially, six-membered lactone cycles are slightly changed upon the nucleophilic attack of phosphine, leading to the stabilizing stereoelectronic effect by the Ρ···Ο interaction. The addition of phosphine to α-methylene-γ-butyrolactam significantly distorts the initial geometry of the heterocycle, making the nucleophilic attack unfavorable. The application of the stereoelectronic effect to enhance the efficiency of the phosphine-catalyzed Michael and Pudovik reactions of α-methylene lactones was demonstrated.
Collapse
Affiliation(s)
- Alexey V Salin
- A.M. Butlerov Institute of Chemistry,Kazan Federal University, Kremlevskaya Street 18, Kazan 420008, Russian Federation
| | - Andrey A Shabanov
- A.M. Butlerov Institute of Chemistry,Kazan Federal University, Kremlevskaya Street 18, Kazan 420008, Russian Federation
| | - Khasan R Khayarov
- A.M. Butlerov Institute of Chemistry,Kazan Federal University, Kremlevskaya Street 18, Kazan 420008, Russian Federation
| | - Ramil I Nugmanov
- Janssen Research & Development, Janssen Pharmaceutica N.V., Turnhoutseweg 30, Beerse B-2340, Belgium
| | - Daut R Islamov
- Laboratory for Structural Analysis of Biomacromolecules, Kazan Scientific Center of Russian Academy of Science, Kremlevskaya Street 31, Kazan 420008, Russian Federation
| |
Collapse
|
2
|
Arglabin could target inflammasome-induced ARDS and cytokine storm associated with COVID-19. Mol Biol Rep 2021; 48:8221-8225. [PMID: 34655016 PMCID: PMC8519322 DOI: 10.1007/s11033-021-06827-7] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2021] [Accepted: 10/08/2021] [Indexed: 10/28/2022]
Abstract
Arglabin (l(R),10(S)-epoxy-5(S),5(S),7(S)-guaia-3(4),ll(13)-dien-6,12-olide), is a natural sesquiterpene γ-lactone which was first isolated from Artemisia glabella. The compound has been shown to possess anti-inflammatory activity through inhibition of the NLR Family pyrin domain-containing 3 (NLRP3) inflammasome and production of proinflammatory cytokines including interleukin (IL)-1β and IL-18. A more hydrophilic derivative of the compound also exhibited antitumor activity in the breast, colon, ovarian, and lung cancer. Some other synthetic derivatives of the compound have also been synthesized with antitumor, cytotoxic, antibacterial, and antifungal activities. Since both NLRP3 inflammasome and cytokine storm are associated with the pathogenesis of COVID-19 and its lethality, compounds like arglabin might have therapeutic potential to attenuate the inflammasome-induced acute respiratory distress syndrome and/or the cytokine storm associated with COVID-19.
Collapse
|
3
|
Adekenov S, Zhumakayeva A, Perminov V, Bekmanov B, Rakhimov K. Neoadjuvant Therapy with Drug Arglabin for Breast Cancer with Expression of H-Ras Oncoproteins. Asian Pac J Cancer Prev 2020; 21:3441-3447. [PMID: 33247707 PMCID: PMC8033125 DOI: 10.31557/apjcp.2020.21.11.3441] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2020] [Indexed: 01/22/2023] Open
Abstract
BACKGROUNDS In breast cancer, blocking of Ras signaling and inhibition of H-Ras is quite promising. H-Ras may become a target for farnesyl transferase inhibitors, and in combination with other immunohistochemical factors it will contribute to the progression of a breast tumor. PURPOSE The aim of this study was to evaluate the effectiveness of neoadjuvant therapy for breast cancer with the inclusion of farnesyl transferase inhibitor, arglabin interfering with the expression and concentration of H-Ras oncoproteins. METHODS Depending on the presence of H-Ras oncoproteins after Western-blot hybridization, the patients were divided a negative and positive expression of H-Ras groups. RESULTS Correlation analysis of methods used for determining the expression ability and concentration of H-Ras oncoproteins (immunohistochemistry and Western-blot analysis) demonstrated substantial statistical relationship Rs=0.71, p=0.03. The H-Ras oncoproteins were absent in patients receiving either "Arglabin" or standard AC regimen. However, in the AC + Arglabin group, there was a varying degrees of positive concentration of H-Ras oncoproteins (Kruskal-Wallis=6.92; p=0.03). CONCLUSION These results indicate that Arglabin attenuates H-Ras oncoproteins expression which is a promising therapeutic target for breast cancer.
Collapse
Affiliation(s)
- Sergazy Adekenov
- JSC "International Research and Production Holding "Phytochemistry", Karaganda, Republic of Kazakhstan
| | - Ainur Zhumakayeva
- JSC "International Research and Production Holding "Phytochemistry", Karaganda, Republic of Kazakhstan.,Karaganda Medicinal University, Kazakhstan
| | - Vladimir Perminov
- Center of the Multidisciplinary Hospital No 3 of the Health Administration of the Karaganda Region, Kazakhstan
| | - Bakhytzhan Bekmanov
- Institute of General Genetics and Cytology, Kazakhstan. 5Asfendiyarov Kazakh National Medical University, Kazakhstan
| | - Kayrolla Rakhimov
- JSC "International Research and Production Holding "Phytochemistry", Karaganda, Republic of Kazakhstan.,Asfendiyarov Kazakh National Medical University, Kazakhstan
| |
Collapse
|
4
|
Applications of Sesquiterpene Lactones: A Review of Some Potential Success Cases. APPLIED SCIENCES-BASEL 2020. [DOI: 10.3390/app10093001] [Citation(s) in RCA: 52] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Sesquiterpene lactones, a vast range of terpenoids isolated from Asteraceae species, exhibit a broad spectrum of biological effects and several of them are already commercially available, such as artemisinin. Here the most recent and impactful results of in vivo, preclinical and clinical studies involving a selection of ten sesquiterpene lactones (alantolactone, arglabin, costunolide, cynaropicrin, helenalin, inuviscolide, lactucin, parthenolide, thapsigargin and tomentosin) are presented and discussed, along with some of their derivatives. In the authors’ opinion, these compounds have been neglected compared to others, although they could be of great use in developing important new pharmaceutical products. The selected sesquiterpenes show promising anticancer and anti-inflammatory effects, acting on various targets. Moreover, they exhibit antifungal, anxiolytic, analgesic, and antitrypanosomal activities. Several studies discussed here clearly show the potential that some of them have in combination therapy, as sensitizing agents to facilitate and enhance the action of drugs in clinical use. The derivatives show greater pharmacological value since they have better pharmacokinetics, stability, potency, and/or selectivity. All these natural terpenoids and their derivatives exhibit properties that invite further research by the scientific community.
Collapse
|
5
|
Divergent synthesis and identification of the cellular targets of deoxyelephantopins. Nat Commun 2016; 7:12470. [PMID: 27539788 PMCID: PMC4992173 DOI: 10.1038/ncomms12470] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2016] [Accepted: 06/23/2016] [Indexed: 12/12/2022] Open
Abstract
Herbal extracts containing sesquiterpene lactones have been extensively used in traditional medicine and are known to be rich in α,β-unsaturated functionalities that can covalently engage target proteins. Here we report synthetic methodologies to access analogues of deoxyelephantopin, a sesquiterpene lactone with anticancer properties. Using alkyne-tagged cellular probes and quantitative proteomics analysis, we identified several cellular targets of deoxyelephantopin. We further demonstrate that deoxyelephantopin antagonizes PPARγ activity in situ via covalent engagement of a cysteine residue in the zinc-finger motif of this nuclear receptor. Deoxyelephantopin is a naturally occurring sesquiterpene lactone with known anticancer properties. Here, the authors synthesize deoxyelephantopins and a range of analogues including alkyne-tagged probes, using them to identify its cellular targets.
Collapse
|
6
|
Molnár J, Szebeni GJ, Csupor-Löffler B, Hajdú Z, Szekeres T, Saiko P, Ocsovszki I, Puskás LG, Hohmann J, Zupkó I. Investigation of the Antiproliferative Properties of Natural Sesquiterpenes from Artemisia asiatica and Onopordum acanthium on HL-60 Cells in Vitro. Int J Mol Sci 2016; 17:83. [PMID: 26901188 PMCID: PMC4783873 DOI: 10.3390/ijms17020083] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2015] [Revised: 12/10/2015] [Accepted: 12/29/2015] [Indexed: 11/16/2022] Open
Abstract
Plants and plant extracts play a crucial role in the research into novel antineoplastic agents. Four sesquiterpene lactones, artecanin (1), 3β-chloro-4α,10α-dihydroxy-1α,2α-epoxy-5α,7αH-guaia-11(13)-en-12,6α-olide (2), iso-seco-tanapartholide 3-O-methyl ether (3) and 4β,15-dihydro-3-dehydrozaluzanin C (4), were isolated from two traditionally used Asteraceae species (Onopordum acanthium and Artemisia asiatica). When tested for antiproliferative action on HL-60 leukemia cells, these compounds exhibited reasonable IC50 values in the range 3.6–13.5 μM. Treatment with the tested compounds resulted in a cell cycle disturbance characterized by increases in the G1 and G2/M populations, while there was a decrease in the S phase. Additionally, 1–3 elicited increases in the hypodiploid (subG1) population. The compounds elicited concentration-dependent chromatin condensation and disruption of the membrane integrity, as revealed by Hoechst 33258–propidium staining. Treatment for 24 h resulted in significant increases in activity of caspases-3 and -9, indicating that the tested sesquiterpenes induced the mitochondrial pathway of apoptosis. The proapoptotic properties of the sesquiterpene lactones were additionally demonstrated withannexin V staining. Compounds 1 and 2 increased the Bax/Bcl-2 expression and decreased the expressions of CDK1 and cyclin B2, as determined at the mRNA level by means of RT-PCR. These experimental results indicate that sesquiterpene lactones may be regarded as potential starting structures for the development of novel anticancer agents.
Collapse
Affiliation(s)
- Judit Molnár
- Department of Pharmacodynamics and Biopharmacy, University of Szeged, H-6720 Szeged, Hungary.
| | | | | | - Zsuzsanna Hajdú
- Department of Pharmacognosy, University of Szeged, H-6720 Szeged, Hungary.
| | - Thomas Szekeres
- Department of Medical and Chemical Laboratory Diagnostics, Medical University of Vienna, A-1090 Vienna, Austria.
| | - Philipp Saiko
- Department of Medical and Chemical Laboratory Diagnostics, Medical University of Vienna, A-1090 Vienna, Austria.
| | - Imre Ocsovszki
- Department of Biochemistry, University of Szeged, H-6720 Szeged, Hungary.
| | | | - Judit Hohmann
- Department of Pharmacognosy, University of Szeged, H-6720 Szeged, Hungary.
| | - István Zupkó
- Department of Pharmacodynamics and Biopharmacy, University of Szeged, H-6720 Szeged, Hungary.
| |
Collapse
|
7
|
Regulating against the dysregulation: new treatment options in autoinflammation. Semin Immunopathol 2015; 37:429-37. [PMID: 26059720 DOI: 10.1007/s00281-015-0501-9] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2015] [Accepted: 05/14/2015] [Indexed: 12/29/2022]
Abstract
In autoinflammatory disorders, dysregulation of the innate immune response leads to an excessive cytokine release. The disease course is often characterized by high morbidity and mortality, treatment is mostly difficult and therapeutic options are limited. In most cases, life-long control of ongoing inflammation is necessary in order to improve clinical symptoms and prevent development of damage. Steroids are helpful in many conditions, but the development of serious side effects often limits their long-term use. Other immunosuppressive, steroid-sparing medications are less effective than in the treatment of autoimmune diseases or do not show any effect. So far, anti-IL1α and/or β-blocking agents as well as an IL-6 receptor-blocking monoclonal antibody and, to a lesser extent, TNF-α blocking agents were applied in autoinflammatory disorders and significantly improved the outcome. Although these progresses were made in the last years, there are still numerous challenges in order to improve drug therapy in autoinflammation. This review summarizes the current state of new drug development and discusses advantages and disadvantages of possible targets.
Collapse
|
8
|
Jia QQ, Wang JC, Long J, Zhao Y, Chen SJ, Zhai JD, Wei LB, Zhang Q, Chen Y, Long HB. Sesquiterpene lactones and their derivatives inhibit high glucose-induced NF-κB activation and MCP-1 and TGF-β1 expression in rat mesangial cells. Molecules 2013; 18:13061-77. [PMID: 24152676 PMCID: PMC6269856 DOI: 10.3390/molecules181013061] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2013] [Revised: 09/12/2013] [Accepted: 10/14/2013] [Indexed: 01/13/2023] Open
Abstract
Diabetic nephropathy (DN) is one of the most common and serious chronic complications of diabetes mellitus, however, no efficient clinical drugs exist for the treatment of DN. We selected and synthesized several sesquiterpene lactones (SLs), and then used the MTT assay to detect rat mesangial cells (MCs) proliferation, ELISA to measure the expression level of monocyte chemoattractant protein-1 (MCP-1), transforming growth factor beta (TGF-β1) and fibronectin(FN), real-time fluorescent quantitative PCR analysis to measure the MCP-1 and TGF-β1 gene expression, western blot to detect the level of IκBα protein and EMSA to measure the activation of nuclear factor kappa B (NF-κB). We discovered that SLs, including parthenolide (PTL), micheliolide (MCL), arglabin, and isoalantolactone (IAL), as well as several synthetic analogs of these molecules, could effectively attenuate the high glucose-stimulated activation of NF-κB, the degradation of IκBα, and the expression of MCP-1, TGF-β1 and FN in rat mesangial cells (MCs). These findings suggest that SLs and their derivatives have potential as candidate drugs for the treatment of DN.
Collapse
Affiliation(s)
- Qian-Qian Jia
- Department of Nephrology, Zhujiang Hospital, Southern Medical University, Guangzhou 510000, China; E-Mails: (Q.-Q.J.); (J.-C.W.); (Y.Z); (S.-J.C.); (L.-B.W.)
| | - Jian-Cheng Wang
- Department of Nephrology, Zhujiang Hospital, Southern Medical University, Guangzhou 510000, China; E-Mails: (Q.-Q.J.); (J.-C.W.); (Y.Z); (S.-J.C.); (L.-B.W.)
| | - Jing Long
- College of Pharmacy, the State Key Laboratory of Elemento-Organic Chemistry, and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tianjin 300071, China; E-Mails: (J.L.); (J.-D.Z.); (Q.Z.); (Y.C.)
| | - Yan Zhao
- Department of Nephrology, Zhujiang Hospital, Southern Medical University, Guangzhou 510000, China; E-Mails: (Q.-Q.J.); (J.-C.W.); (Y.Z); (S.-J.C.); (L.-B.W.)
| | - Si-Jia Chen
- Department of Nephrology, Zhujiang Hospital, Southern Medical University, Guangzhou 510000, China; E-Mails: (Q.-Q.J.); (J.-C.W.); (Y.Z); (S.-J.C.); (L.-B.W.)
| | - Jia-Dai Zhai
- College of Pharmacy, the State Key Laboratory of Elemento-Organic Chemistry, and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tianjin 300071, China; E-Mails: (J.L.); (J.-D.Z.); (Q.Z.); (Y.C.)
| | - Lian-Bo Wei
- Department of Nephrology, Zhujiang Hospital, Southern Medical University, Guangzhou 510000, China; E-Mails: (Q.-Q.J.); (J.-C.W.); (Y.Z); (S.-J.C.); (L.-B.W.)
| | - Quan Zhang
- College of Pharmacy, the State Key Laboratory of Elemento-Organic Chemistry, and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tianjin 300071, China; E-Mails: (J.L.); (J.-D.Z.); (Q.Z.); (Y.C.)
| | - Yue Chen
- College of Pharmacy, the State Key Laboratory of Elemento-Organic Chemistry, and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tianjin 300071, China; E-Mails: (J.L.); (J.-D.Z.); (Q.Z.); (Y.C.)
| | - Hai-Bo Long
- Department of Nephrology, Zhujiang Hospital, Southern Medical University, Guangzhou 510000, China; E-Mails: (Q.-Q.J.); (J.-C.W.); (Y.Z); (S.-J.C.); (L.-B.W.)
- Authors to whom correspondence should be addressed; E-Mail: ; Tel./Fax: +86-20-6278-2305
| |
Collapse
|
9
|
Becker JVW, van der Merwe MM, van Brummelen AC, Pillay P, Crampton BG, Mmutlane EM, Parkinson C, van Heerden FR, Crouch NR, Smith PJ, Mancama DT, Maharaj VJ. In vitro anti-plasmodial activity of Dicoma anomala subsp. gerrardii (Asteraceae): identification of its main active constituent, structure-activity relationship studies and gene expression profiling. Malar J 2011; 10:295. [PMID: 21985233 PMCID: PMC3200184 DOI: 10.1186/1475-2875-10-295] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2011] [Accepted: 10/11/2011] [Indexed: 12/04/2022] Open
Abstract
Background Anti-malarial drug resistance threatens to undermine efforts to eliminate this deadly disease. The resulting omnipresent requirement for drugs with novel modes of action prompted a national consortium initiative to discover new anti-plasmodial agents from South African medicinal plants. One of the plants selected for investigation was Dicoma anomala subsp. gerrardii, based on its ethnomedicinal profile. Methods Standard phytochemical analysis techniques, including solvent-solvent extraction, thin-layer- and column chromatography, were used to isolate the main active constituent of Dicoma anomala subsp. gerrardii. The crystallized pure compound was identified using nuclear magnetic resonance spectroscopy, mass spectrometry and X-ray crystallography. The compound was tested in vitro on Plasmodium falciparum cultures using the parasite lactate dehydrogenase (pLDH) assay and was found to have anti-malarial activity. To determine the functional groups responsible for the activity, a small collection of synthetic analogues was generated - the aim being to vary features proposed as likely to be related to the anti-malarial activity and to quantify the effect of the modifications in vitro using the pLDH assay. The effects of the pure compound on the P. falciparum transcriptome were subsequently investigated by treating ring-stage parasites (alongside untreated controls), followed by oligonucleotide microarray- and data analysis. Results The main active constituent was identified as dehydrobrachylaenolide, a eudesmanolide-type sesquiterpene lactone. The compound demonstrated an in vitro IC50 of 1.865 μM against a chloroquine-sensitive strain (D10) of P. falciparum. Synthetic analogues of the compound confirmed an absolute requirement that the α-methylene lactone be present in the eudesmanolide before significant anti-malarial activity was observed. This feature is absent in the artemisinins and suggests a different mode of action. Microarray data analysis identified 572 unique genes that were differentially expressed as a result of the treatment and gene ontology analysis identified various biological processes and molecular functions that were significantly affected. Comparison of the dehydrobrachylaenolide treatment transcriptional dataset with a published artesunate (also a sesquiterpene lactone) dataset revealed little overlap. These results strengthen the notion that the isolated compound and the artemisinins have differentiated modes of action. Conclusions The novel mode of action of dehydrobrachylaenolide, detected during these studies, will play an ongoing role in advancing anti-plasmodial drug discovery efforts.
Collapse
|